Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O94864

UPID:
ST65G_HUMAN

ALTERNATIVE NAMES:
Adenocarcinoma antigen ART1; SPTF-associated factor 65 gamma; Suppressor of Ty 7-like

ALTERNATIVE UPACC:
O94864; B4E3W3; Q6IB21; Q9H2T6

BACKGROUND:
STAGA complex 65 subunit gamma, known alternatively as Adenocarcinoma antigen ART1, SPTF-associated factor 65 gamma, and Suppressor of Ty 7-like, is integral to the STAGA transcription coactivator complex. This protein's contribution to gene expression regulation and its potential impact on cellular function highlight the significance of its study in the field of molecular biology and genetics.

THERAPEUTIC SIGNIFICANCE:
The exploration of STAGA complex 65 subunit gamma's role presents a promising avenue for the development of novel therapeutic approaches. By advancing our understanding of this protein, researchers may unlock new strategies to combat diseases through targeted molecular interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.